The authors assessed bronchospasm management in a group of 10 patients aged 44 to 72 yr with chronic reversible bronchoconstriction (4 patients with chronic bronchial asthma and 6 with chronic obstructive bronchitis). A single-blind, cross-over, clinical trial was undertaken according to a random scheme by using, successively, three different treatments (ipratropium alone, beclomethasone alone, the two drugs associated to be noted that in the association the daily doses of both components were reduced to 5/8 of the doses of the non-associated drugs): each treatment lasted 8 days with 3 days of wash-out. The modifications induced by the drugs were evaluated by the assessment of the pulmonary function (FEV1, FRC, FEV1/VCx100,SGaw, FEF(25-75),pH, PaO2, PaCO2), and the daily check of FEV1, of the main cardiovascular parameters (HR, BP max, BP min) and of the possible subjective or objective side-effects. Before the beginning of the trial all patients were treated continuously with theophylline, beta-2-sympathomimetics and corticosteroids, differently associated. The functional variables showed no significant changes between the data at the end of the previous treatment and the same data at the end of every aerosol-administered treatment. Neither subjective nor objective side-effects were observed during any treatment. These results confirm our opinion that beclomethasone dipropionate and ipratropium bromide administered by aerosol are a safe and effective alternative to oral and parenteral drugs in many cases of chronic reversible bronchoconstriction.
|Translated title of the contribution||Bronchospasm management by means of ipratropium, beclomethasone and their combination|
|Title of host publication||Giornale Italiano della Malattie del Torace|
|Number of pages||4|
|Publication status||Published - 1980|
ASJC Scopus subject areas